In conversation with Darren Kelly, CEO of Certa Therapeutics and OccuRx – Fierce Biotech
Melbourne, Australia, 26 November 2019, written by Amirah Al Idrus: At first glance, Darren Kelly doesn’t seem to sleep. He’s the CEO of not one but two fibrosis-related biotechs, an entrepreneur in residence at Brandon Capital, Australia’s largest life sciences-focused VC firm, a director at the Centre for Eye Research Australia and—to top it all […]
OccuRx team to meet with biotech industry leaders during BIO conference in Philadelphia
Melbourne, Australia, 03 June 2019: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s Biotechnology Innovation Organisation (BIO) International Convention will be attended by OccuRx and its management team including Chief Executive Officer, Professor Darren Kelly. The BIO convention is set to take place in […]
OccuRx presents new research at ARVO conference in Vancouver
Melbourne, Australia, 28 April 2019: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce that we will be presenting at the Association for Research in Vision and Ophthalmology (ARVO). OccuRx will present its new research titled ‘Oral administration of the novel small […]
OccuRx to highlight inflammation and fibrosis strategies while attending 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Melbourne, Australia, 07 January 2019: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. OccuRx and its management team including Chief Executive Officer, Professor Darren Kelly will attend 37th Annual J.P. Morgan Health Conference in San Francisco. The OccuRx team will highlight their scientific advancements in anti-inflammatory […]
OccuRx presenting at the European Retinal Meeting in Paris
Melbourne, Australia, 05 October 2017: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to present at the European Retinal Meeting in Paris. OccuRx has been accepted for both an oral and poster presentation at the scientific meeting between 5th -7th October 2017. The […]
OccuRx presents at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Baltimore
Melbourne, Australia, 01 May 2017: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases is pleased to announce it will present at the Association for Research in Vision and Ophthalmology (ARVO) annual scientific meeting next week. OccuRx will present two separate posters at the conference that […]
OccuRx launches with up to AU$6.5M in funding
Melbourne, Australia, 18 May 2015: OccuRx, an Australian biopharmaceutical company developing a new class of drugs to prevent a significant health burden associated with fibrosis, was launched today with up to AU$6.5M in staged tranches of venture capital funding from a consortium including the Medical Research Commercialisation Fund (MRCF), Brandon Capital Partners and Uniseed. At […]
